PhRMA weighs in on ICER reviews reform

24 June 2019

The Institute for Clinical and Economic Review’s (ICER), which styles itself as the USA’s cost-effectiveness watchdog for medicines, has been seeking views on how to improve its value assessment framework and methods.

Never one to hold back, the USA’s main trade group, Pharmaceutical Research and Manufacturers of America (PhRMA) has had its say on behalf of pharma companies.

PhRMA has called itself a strong supporter of value-driven healthcare, including the use of rigorous value frameworks and evidence to support healthcare decision-making, but it has taken issue with certain ICER methodology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK